8-K/A filing — BioKey (Cayman), Inc.

Adicet Bio Reveals FDA Clearance Of IND Application For ADI-212; Co Plans To Initiate Phase 1 Enrollment In Patients With mCRPC In Q4 Of 2026

Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR T cell and in vivo CAR T therapies for autoimmune diseases, hematologic malignancies and solid

Workday Q2 Adj. EPS $2.75 Beats $2.61 Estimate, Sales $2.649B Beat $2.636B Estimate

Workday (NASDAQ:WDAY) reported quarterly earnings of $2.75 per share which beat the analyst consensus estimate of $2.61 by 5.36 percent. This is a 24.43 percent increase over earnings of $2.21 per share from the same

Autodesk Q2 Adj. EPS $3.30 Beats $3.12 Estimate, Sales $2.046B Beat $2.012B Estimate

Autodesk (NASDAQ:ADSK) reported quarterly earnings of $3.30 per share which beat the analyst consensus estimate of $3.12 by 5.77 percent. This is a 25.95 percent increase over earnings of $2.62 per share from the same

Autodesk Sees Q3 GAAP EPS $1.57-$1.87 vs $2.16 Est

Autodesk (NASDAQ:ADSK) is looking for Q3 GAAP EPS of $1.57-$1.87 vs $2.16 analyst estimate..

Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days

Why Nutanix Stock Is Soaring Today

Nutanix stock surged 9.87% after reporting Q4 2026 results that beat analyst expectations with $757.1 million in revenue (16% YoY growth) and $0.60 diluted EPS versus $0.49 expected. The company also generated strong free cash flow of $277.6 million and provided optimistic fiscal 2027 guidance of $3.18-$3.23 billion in revenue and $850-$950 million in free cash flow.